Patent: 10,035,843
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Summary for Patent: 10,035,843
Title: | RSV-specific binding molecule |
Abstract: | The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV. Nucleic acid sequences encoding said antibody, as well as antibody producing cells and methods for producing said antibody are also provided. |
Inventor(s): | Beaumont; Tim (Ouderkerk aan de Amstel, NL), Bakker; Adrianus Q. (Hoorn, NL), Yasuda; Etsuko (Amsterdam, NL) |
Assignee: | MedImmune Limited (Cambridge, GB) |
Application Number: | 15/042,656 |
Patent Claims: | see list of patent claims |
Details for Patent 10,035,843
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Swedish Orphan Biovitrum Ab (publ) | SYNAGIS | palivizumab | For Injection | 103770 | 06/19/1998 | See Plans and Pricing | 2029-10-06 |
Swedish Orphan Biovitrum Ab (publ) | SYNAGIS | palivizumab | Injection | 103770 | 07/23/2004 | See Plans and Pricing | 2029-10-06 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |